Alexza Expects FDA, EU Regulatory Decisions On Adusave This December
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm has responded to a second “complete response” letter from FDA and to questions from EU regulators regarding its proposed inhalation formulation of antipsychotic loxapine.